LIB Therapeutics
Manufacturing · Ohio, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5375 Medpace Way, Cincinnati, Ohio, 4522...Phone Number
(800) 345-2032Website
www.libtherapeutics.comRevenue
<$5 MillionIndustry
About LIB Therapeutics
LIB Therapeutics is a privately held, commercial-stage biopharmaceutical company focused on developing novel therapies for cardiovascular disease and familial hypercholesterolemia. Their primary product, lerodalcibep, is a third-generation PCSK9 inhibitor designed to provide a convenient, once-monthly subcutaneous dose to help patients achieve lower LDL-C levels. The company aims to address the needs of millions of patients worldwide suffering from atherosclerotic cardiovascular disease and those with severe inherited high cholesterol. Founded in 2015, LIB Therapeutics is committed to expanding treatment options and improving patient outcomes in the field of cardiovascular health.Explore more
LIB Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to LIB Therapeutics
Compare insights from companies similar to LIB Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
LIB Therapeutics Tech Stack
A closer look at the technologies used by LIB Therapeutics
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding LIB Therapeutics
Sign Up For FreeTo access detailed company insights
LIB Therapeutics is a privately held, commercial-stage biopharmaceutical company focused on developing novel therapies for cardiovascular disease and familial hypercholesterolemia. Their primary product, lerodalcibep, is a third-generation PCSK9 inhibitor designed to provide a convenient, once-monthly subcutaneous dose to help patients achieve lowe... Read More
